Promotion is heavy on diabetes sites

Share this article:

More than a quarter of posts on Facebook sites for people with diabetes are promotional, many touting products unapproved by the FDA, a study of diabetes-focused social networks says.

The study, in the Archives of Internal Medicine, looked at 15 sites found via a Google search. The sites varied widely, with membership ranging from 3,074 to more than 300,000 and diverse policies on advertising, sponsorship and membership, One policy uniting almost all of them: running industry advertising.

All but two sites required commenters to register, though many required minimal information, some only asking users for a handle and an email address. Only TuDiabetes (see Headliner, p. 34)“ required an extensive profile to be sent to the site administrator.” Physicians were on hand to answer questions on a third of the sites and more than half used diabetes educators to answer member questions, though those authorities systematically scanned posts on very few sites.

The study's authors wrote that “little is known about the structure of communication, the sources of funding and the presence or use of advertising on these sites.”

“Existing sites differ in their approach toward communication structure, authenticity and quality oversight, expert participation and advertising or sources of funding,” said the report. “These metrics may be important to patients when selecting a community and may be of interest to health care providers who ultimately may advise patients about their particular needs.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...